VIS171

DRUG2 trials

Sponsors

Otsuka Pharmaceutical Development & Commercialization, Inc.

Conditions

Alopecia Areata (AA)Autoimmune DiseasesImmune-mediated Focal Segmental Glomerulosclerosis (FSGS)Systemic Lupus Erythematosus (SLE)

Phase 1

A Study to Evaluate the Safety, PK and PD of VIS171 in Participants (Healthy and With Autoimmune Disease)

CompletedNCT05418101

Otsuka Pharmaceutical Development & Commercialization, Inc.Autoimmune Diseases

Start: 2022-04-28End: 2024-03-13Updated: 2026-04-15

A Phase 1 Trial to Evaluate the Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of VIS171 in Participants With Autoimmune Disease(s)

Active, not recruitingNCT06799520

Otsuka Pharmaceutical Development & Commercialization, Inc.Alopecia Areata (AA), Immune-mediated Focal Segmental Glomerulosclerosis (FSGS), Systemic Lupus Erythematosus (SLE)

Start: 2025-03-17End: 2027-02-19Target: 30Updated: 2026-07-22